Mizuho Reiterates “Buy” Rating for Amgen Inc. (AMGN)
Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by equities researchers at Mizuho in a report released on Friday. They currently have a $198.00 price objective on the medical research company’s stock. Mizuho’s target price suggests a potential upside of 6.55% from the stock’s previous close.
A number of other research analysts have also recently issued reports on AMGN. UBS AG reiterated a “neutral” rating and issued a $175.00 target price (up previously from $174.00) on shares of Amgen in a research report on Tuesday, June 13th. Credit Suisse Group reiterated a “neutral” rating and issued a $186.00 target price (up previously from $177.00) on shares of Amgen in a research report on Friday, September 29th. Morgan Stanley reiterated an “overweight” rating and issued a $196.00 target price (up previously from $189.00) on shares of Amgen in a research report on Friday. Cann restated a “buy” rating and set a $203.00 price target on shares of Amgen in a report on Friday. Finally, Jefferies Group LLC restated a “buy” rating and set a $195.00 price target on shares of Amgen in a report on Tuesday, July 11th. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $189.99.
Amgen (NASDAQ AMGN) opened at 185.82 on Friday. Amgen has a 12 month low of $133.64 and a 12 month high of $191.10. The firm has a market cap of $135.59 billion, a P/E ratio of 16.93 and a beta of 1.36. The company’s 50-day moving average is $181.33 and its 200 day moving average is $170.23. Amgen also was the recipient of some unusual options trading on Thursday. Stock traders purchased 9,350 put options on the company. This represents an increase of approximately 239% compared to the average volume of 2,758 put options.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the business posted $2.84 earnings per share. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts expect that Amgen will post $12.58 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Mizuho Reiterates “Buy” Rating for Amgen Inc. (AMGN)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/08/mizuho-reiterates-buy-rating-for-amgen-inc-amgn.html.
Several institutional investors have recently bought and sold shares of the stock. Beacon Financial Group lifted its stake in shares of Amgen by 9.4% in the third quarter. Beacon Financial Group now owns 46,553 shares of the medical research company’s stock worth $8,680,000 after acquiring an additional 3,990 shares during the period. Eqis Capital Management Inc. lifted its stake in Amgen by 5.8% in the third quarter. Eqis Capital Management Inc. now owns 32,335 shares of the medical research company’s stock valued at $6,029,000 after buying an additional 1,770 shares during the period. Curbstone Financial Management Corp lifted its stake in Amgen by 140.2% in the third quarter. Curbstone Financial Management Corp now owns 3,158 shares of the medical research company’s stock valued at $589,000 after buying an additional 1,843 shares during the period. Perpetual Ltd lifted its stake in Amgen by 4.3% in the second quarter. Perpetual Ltd now owns 7,354 shares of the medical research company’s stock valued at $1,267,000 after buying an additional 300 shares during the period. Finally, Bogart Wealth LLC lifted its stake in Amgen by 13.8% in the second quarter. Bogart Wealth LLC now owns 3,181 shares of the medical research company’s stock valued at $548,000 after buying an additional 385 shares during the period. 78.10% of the stock is currently owned by institutional investors.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.